

# PAMAM-calix-dendrimers

Subjects: Biochemical Research Methods

Contributor: Ivan Stoikov

A convenient method for the synthesis of the first generation PAMAM dendrimers based on the thiacalix[4]arene has been developed for the first time. Three new PAMAM-calix-dendrimers with the macrocyclic core in cone, partial cone, and 1,3-alternate conformations were obtained with high yields.

Keywords: thiacalixarene ; DNA ; dendrimer ; PAMAM


---

## 1. Introduction

In recent years, research aimed at developing DNA vaccines has shown great potential <sup>[1]</sup>. These medicinal products are already successfully used in veterinary medicine <sup>[2]</sup>. Recently, Inovio Pharmaceuticals Corporation (Plymouth Meeting, PA) proposed a DNA vaccine for the prevention of SARS COVID-19 <sup>[3]</sup>. A significant increase in research on the use of DNA-based drugs for the treatment of other diseases has also been noted in recent years <sup>[4]</sup>. Wound-healing, anti-inflammatory, and antithrombotic drugs have been clinically tested and are now commercially available. For example, Jazz Pharmaceuticals proposed the drug Defitelio<sup>®</sup> (defibrotide sodium), which is the oligonucleotide obtained by depolymerization of porcine intestinal mucosal DNA for the treatment of hepatic veno-occlusive disease <sup>[5]</sup>. In addition, polynucleotides obtained from marine fish exert a wide therapeutic use <sup>[6][7][8]</sup>.

The area of scientific research devoted to the development of DNA storage systems has become important due to the widespread application of DNA macromolecules <sup>[9]</sup>. Preservation of nucleic acid-based drugs from enzymatic degradation in the bloodstream is considered an important point <sup>[10]</sup>. The necessity of the storing of biomolecules is not limited to disease therapy. Intensive research has been carried out recently into preserving genetic material long-term to establish kinship and store information <sup>[11][12]</sup>. Among the methods of DNA storing, freezing is of great importance. However, chemical encapsulation is under intensive study as well. It is well known that DNA is able to bind with small molecules in three different ways, i.e., by electrostatic interactions, intercalation, or groove binding. All of these are important in different applications <sup>[13][14][15]</sup>. It is obvious that the structure of DNA can be preserved most closely to the native one during binding via electrostatic interactions; therefore, this is the most convenient method for DNA storing.

Currently, synthetic non-viral DNA delivery and storage systems are intensively developing. Dendrimers capable of forming dendriplexes with DNA are the most promising variants of the synthetic vectors for DNA. Their ability to pH-responsive osmotic swelling and endosomal membrane rupture is undoubtedly important for the transfection of genetic material <sup>[10][16]</sup>. The search for new dendrimeric compounds with fewer disadvantages is an important area of synthetic chemistry. Macrocyclic compounds such as cyclodextrins, pillararenes, and the (thia)calixarenes with positively charged groups are promising for use as a dendrimer core for binding DNA as a biological polyanion <sup>[17][18][19]</sup>. We used thiacalix[4]arene as a core of dendrimer compounds. (Thia)calixarene scaffold is non-toxic. It is known that the covalent binding of various toxic molecules with (thia)calixarene scaffold decreases their toxicity <sup>[20][21]</sup>. The possibility of easy synthesis of stereoisomers with different spatial arrangements of substituents is another advantage of the thiacalixarene platform. Relatively rigid spatial fixation of binding groups provides high selectivity of guest molecule binding <sup>[22][23][24]</sup>. It should be noted that the thiacalixarene scaffold exerts a multivalent binding effect <sup>[25][26]</sup> by fixing binding sites in space, which is very important in the case of DNA <sup>[27]</sup>. The use of thiacalix[4]arene in *cone*, *partial cone*, and *1,3-alternate* conformation will lead to different shapes of the resulting dendrimers. True symmetric dendrimer shape in case of the core with the macrocycle in *1,3-alternate* conformation, as well as asymmetrical shape <sup>[10]</sup> in case of those in *cone* and *partial cone* conformation, can be expected (**Figure 1**). In the dendrimer with the core in *cone* conformation (**Figure 1**), the hydrophilic dendritic part and lipophilic macrocyclic part will be strictly parted. The uniqueness of this structure is that it is amphiphilic, contrary to classical dendrimers. By using dendrimers of a different shape described above for the DNA binding, we will be able not only to achieve the multivalency effect of binding but also to obtain dendriplexes of different structures.



**Figure 1.** Schematic representation of the design of thiacalix[4]arene-based dendrimers.

## 2. Synthesis of (Poly)Amidoamine Dendrimers Based on the p-tert-Buthylthiacalix[4]arene (PAMAM-Calix-Dendrimer) in Different Conformations

Synthesis of the poly(amidoamine) (PAMAM) dendrimers is well described in the literature [28][29]. The divergent approach is the optimal one to their synthesis. It involves the use of repetitive sequences of reactions. First, the core containing primary amino groups is introduced into the Michael addition reaction with methyl acrylate for branching. Then, the obtained precursor (called half-generation) is involved in the reaction with an excess of the diamine. This leads to the formation of a full generation of the PAMAM dendrimer. Side reactions during the synthesis of dendrimers often cause defects in their structure. The literature [30][31] describes both the range of possible side reactions and the main methods for preventing their occurrence.

Despite a large number of advantages in the application of the PAMAM dendrimers [16][29], they have a number of significant disadvantages and limitations. The most significant is the increase of in vivo and in vitro cytotoxicity of dendrimers in the direction from lower to higher generation and, accordingly, the high toxicity of upper generations dendrimers [32]. Cytotoxicity of the high generation dendrimers is due to a large number of positive charges on their surface, which can induce morphological changes in cells or cause cell lysis by disrupting the integrity of the negatively charged phospholipid bilayers of the cell membranes [33]. The structure of dendrimeric molecules with classical core not capable of serious conformational changes is another limitation. Therefore, the shape of such dendrimer molecules is close to spherical. In addition, despite the fact that currently, PAMAM dendrimers are commercially available up to generation 10, the cost of upper generation ( $G > 3$ ) dendrimers is high [34].

The size of thiacalix[4]arene [22] is comparable to that of the PAMAM dendrimers of lower generations with ethylenediamine (EDA) core [29]. The PAMAM dendrimers of 1st–3rd generation with thiacalix[4]arene core are assumed to be comparable in size with the dendrimers with the EDA core of higher generations. In addition, the interior void space of the thiacalix[4]arene-based dendrimer will be significantly larger. This allows obtaining dendrimers that can effectively bind biopolymers and other guest molecules using fewer steps of the synthesis.

Our approach combines the advantages of dendrimers and thiacalixarenes and reduces their disadvantages. It will make it possible to obtain low-toxic dendrimer macromolecules with a wide internal void that are capable of efficient multi-point interaction with substrates.

There are few examples of the synthesis of low generation dendrimers based on classical calix[4]arene in the literature [35][36]. They are limited by the use of calixarene in one spatial conformation, either *cone* or *1,3-alternate*. It is also worth noting that there are no examples of the synthesis of high generation ( $G > 2$ ) PAMAM dendrimers based on the thiacalix[4]arene platform.

In one recent publication [37], the authors described an improved approach to the synthesis and purification of the PAMAM dendrimers with a 1,4-diaminobutane core based on Tomalia's previous works [29][38]. This approach allows to minimize the probability of side reactions and to obtain the PAMAM dendrimers in high yields. We have adapted this method to the synthesis of thiacalixarene-based dendrimers.

We have chosen the macrocyclic compounds **G0** in *cone* (**G0-cone**), *partial cone* (**G0-paco**), and *1,3-alternate* (**G0-1,3-alt**) conformation [26] as cores for the synthesis of the PAMAM dendrimers based on thiacalix[4]arene. Hereby they are named as PAMAM-calix-dendrimers. Starting compounds contain four primary amino groups in their structure. This makes it possible to effectively apply a divergent approach for the dendrimer synthesis (**Scheme 1**). In order to minimize the possibility of side reactions, the temperature did not exceed 30 °C at all stages of the synthesis, isolation, and purification.

**Scheme 1.** Reagents and conditions: (i) methyl acrylate, methanol, r.t., 12 h; (ii) ethylenediamine, methanol, r.t., 70 h.

Thus, an efficient method for the synthesis of the first generation PAMAM-calix-dendrimers dendrimers **G1** and their precursors (half-generation) **G0.5** has been developed. The structure and composition of the obtained compounds **G0.5** and **G1** were confirmed by  $^1\text{H}$ ,  $^{13}\text{C}$  NMR, IR spectroscopy, mass spectrometry, and elemental analysis.

Compared to **G1-1,3-alt**, chemical shifts of the aryl protons in the **G1-cone** drifted upfield (7.45 ppm for **G1-cone** against 7.59 ppm for **G1-1,3-alt**) due to the shielding effect of neighboring aryl fragments on the aryl protons of the macrocycle ring. Similarly, the peaks of the *tert*-butyl groups of the **G1-cone** were also shifted upfield (1.14 ppm) compared to corresponding peaks for the **G1-1,3-alt** (1.28 ppm).

In the case of the asymmetric compound **G1-paco**, symmetry of the macrocyclic core was disturbed, and this complicated the spectra. The peaks of the *tert*-butyl fragment appeared as two singlets at 1.09 and 1.35 ppm with a ratio of 1:1, peaks of protons of aromatic and oxymethylene groups formed two singlets and AB system.

It should be noted that many chemical shifts of branching proton signals coincided in comparison to the  $^1\text{H}$  NMR spectra of three compounds **G1-cone**, **G1-paco**, and **G1-1,3-alt**. This occurs even in the NMR spectrum of the compound **G1-paco**, although the NMR spectra of the thiacalix[4]arene derivatives in *partial cone* conformation are usually complicated due to the disturbance of the symmetry of the macrocyclic platform. Thus, in all three stereoisomers, the proton signals of the methylene groups of branching appeared in the same areas (2.36, 2.46, 2.65–2.80, and 3.24 ppm). This is probably due to the decreasing influence of the macrocycle conformation resulting from the distancing of mentioned groups from the macrocyclic platform. Besides, the obtained NMR data indicates the purity of the synthesized first-generation PAMAM-calix-dendrimers and the absence of defects in their structure.

The obtained compounds **G0.5** and **G1** were also characterized by mass spectrometry. For example, ESI high-resolution mass spectra of the compounds **G1** showed peaks corresponding to molecular ions with three, four, five and six protons ( $[\text{M} + 3\text{H}]^{3+}$ ,  $[\text{M} + 4\text{H}]^{4+}$ ,  $[\text{M} + 5\text{H}]^{5+}$ , and  $[\text{M} + 6\text{H}]^{6+}$ ).

Thus, the novel first generation of PAMAM-calix-dendrimers was designed and synthesized with high yields. The structure of the obtained compounds was proven by modern physical methods.

---

## References

1. Rodríguez-Gascón, A.; del Pozo-Rodríguez, A.; Solinis, M.A. Development of nucleic acid vaccines: Use of self-amplifying RNA in lipid nanoparticles. *Int. J. Nanomed.* 2014, 9, 1833–1843.
2. Zygmuntowicz, A.; Burmańczuk, A.; Markiewicz, W. Selected Biological Medicinal Products and Their Veterinary Use. *Animals* 2020, 10, 2343.
3. Sharpe, H.R.; Gilbride, C.; Allen, E.; Belij-Rammerstorfer, S.; Bissett, C.; Ewer, K.; Lambe, T. The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. *Immunology* 2020, 160, 223–232.
4. Yamakawa, K.; Nakano-Narusawa, Y.; Hashimoto, N.; Yokohira, M.; Matsuda, Y. Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment. *Int. J. Mol. Sci.* 2019, 20, 4224.
5. Pescador, R.; Capuzzi, L.; Mantovani, M.; Fulgenzi, A.; Ferrero, M. Defibrotide: Properties and clinical use of an old/new drug. *Vasc. Pharmacol.* 2013, 59, 1–10.
6. Squadrito, F.; Bitto, A.; Irrera, N.; Pizzino, G.; Pallio, G.; Minutoli, L.; Altavilla, D. Pharmacological Activity and Clinical Use of PDRN. *Front. Pharmacol.* 2017, 8, 224.
7. Lee, D.-W.; Hyun, H.; Lee, S.; Kim, S.-Y.; Kim, G.-T.; Um, S.; Hong, S.O.; Chun, H.J.; Yang, D.H. The Effect of Polydeoxyribose Nucleotide Extracted from Salmon Sperm on the Restoration of Bisphosphonate-Related Osteonecrosis of the Jaw. *Mar. Drugs* 2019, 17, 51.
8. Kim, T.-H.; Heo, S.-Y.; Oh, G.-W.; Heo, S.-J.; Jung, W.-K. Applications of Marine Organism-Derived Polydeoxyribose Nucleotide: Its Potential in Biomedical Engineering. *Mar. Drugs* 2021, 19, 296.
9. Matange, K.; Tuck, J.M.; Keung, A.J. DNA stability: A central design consideration for DNA data storage systems. *Nat. Commun.* 2021, 12, 1–9.
10. Mendes, L.P.; Pan, J.; Torchilin, V.P. Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy. *Molecules* 2017, 22, 1401.
11. Ceze, L.; Nivala, J.; Strauss, K. Molecular digital data storage using DNA. *Nat. Rev. Genet.* 2019, 20, 456–466.
12. Tan, X.; Ge, L.; Zhang, T.; Lu, Z. Preservation of DNA for data storage. *Russ. Chem. Rev.* 2021, 90, 280–291.
13. Gibson, D.S. Drug–DNA interactions and novel drug design. *Pharmacogenomics J.* 2002, 2, 275–276.
14. Portugal, J.; Barceló, F. Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents. *Curr. Med. Chem.* 2016, 23, 4108–4134.

15. Khadieva, A.; Mostovaya, O.; Padnya, P.; Kalinin, V.; Grishaev, D.; Tumakov, D.; Stoikov, I. Arylamine Analogs of Methylene Blue: Substituent Effect on Aggregation Behavior and DNA Binding. *Int. J. Mol. Sci.* 2021, 22, 5847.
16. Pedziwiatr-Werbicka, E.; Milowska, K.; Dzitruk, V.; Ionov, M.; Shcharbin, D.; Bryszewska, M. Dendrimers and hyperbranched structures for biomedical applications. *Eur. Polym. J.* 2019, 119, 61–73.
17. Padnya, P.L.; Andreyko, E.A.; Mostovaya, O.A.; Rizvanov, I.K.; Stoikov, I.I. The synthesis of new amphiphilic p-tert-butylthiacalixarenes containing peptide fragments and their interaction with DNA. *Org. Biomol. Chem.* 2015, 13, 5894–5904.
18. Yakimova, L.S.; Nugmanova, A.R.; Mostovaya, O.A.; Vavilova, A.A.; Shurpik, D.N.; Mukhametzyanov, T.A.; Stoikov, I.I. Nanostructured Polyelectrolyte Complexes Based on Water-Soluble Thiacalixarene and Pillararene: Self-Assembly in Micelleplexes and Polyplexes at Packaging DNA. *Nanomaterials* 2020, 10, 777.
19. Gallego-Yerga, L.; Lomazzi, M.; Franceschi, V.; Sansone, F.; Mellet, C.O.; Donofrio, G.; Casnati, A.; Fernández, J.M.G. Cyclodextrin- and calixarene-based polycationic amphiphiles as gene delivery systems: A structure–activity relationship study. *Org. Biomol. Chem.* 2014, 13, 1708–1723.
20. Basilotta, R.; Mannino, D.; Filippone, A.; Casili, G.; Prestifilippo, A.; Colarossi, L.; Raciti, G.; Esposito, E.; Campolo, M. Role of Calixarene in Chemotherapy Delivery Strategies. *Molecules* 2021, 26, 3963.
21. Shurpik, D.N.; Padnya, P.L.; Stoikov, I.I.; Cragg, P.J. Antimicrobial Activity of Calixarenes and Related Macrocycles. *Molecules* 2020, 25, 5145.
22. Morohashi, N.; Narumi, F.; Iki, N.; Hattori, A.T.; Miyano, S. Thiacalixarenes. *Chem. Rev.* 2006, 106, 5291–5316.
23. Mostovaya, O.A.; Gorbachuk, V.V.; Padnya, P.; Vavilova, A.A.; Evtugyn, G.A.; Stoikov, I.I. Modification of Oligo- and Polyamides with Macrocyclic Fragments: Synthesis and Properties. *Front. Chem.* 2019, 7, 554.
24. Fasting, C.; Schalley, C.A.; Weber, M.; Seitz, O.; Hecht, S.; Koksche, B.; Dornedde, J.; Graf, C.; Knapp, E.-W.; Haag, R. Multivalency as a Chemical Organization and Action Principle. *Angew. Chem. Int. Ed.* 2012, 51, 10472–10498.
25. Antipin, I.S.; Alfimov, M.V.; Arslanov, V.V.; Burilov, V.A.; Vatsadze, S.Z.; Voloshin, Y.Z.; Volcho, K.P.; Gorbachuk, V.V.; Gorbunova, Y.G.; Gromov, S.P.; et al. Functional supramolecular systems: Design and applications. *Russ. Chem. Rev.* 2021, 90, 895–1107.
26. Mostovaya, O.; Padnya, P.; Shurpik, D.; Shiabiev, I.; Stoikov, I. Novel lactide derivatives of p-tert-butylthiacalixarene: Directed synthesis and molecular recognition of catecholamines. *J. Mol. Liq.* 2020, 327, 114806.
27. Ahmed, M. Peptides, polypeptides and peptide–polymer hybrids as nucleic acid carriers. *Biomater. Sci.* 2017, 5, 2188–2211.
28. Lyu, Z.; Ding, L.; Huang, A.-T.; Kao, C.-L.; Peng, L. Poly(amidoamine) dendrimers: Covalent and supramolecular synthesis. *Mater. Today Chem.* 2019, 13, 34–48.
29. Tomalia, D.A.; Frechet, J. Discovery of dendrimers and dendritic polymers: A brief historical perspective\*. *J. Polym. Sci. Part A: Polym. Chem.* 2002, 40, 2719–2728.
30. Kallos, G.J.; Tomalia, D.A.; Hedstrand, D.M.; Lewis, S.; Zhou, J. Molecular weight determination of a polyamidoamine Starburst polymer by electrospray ionization mass spectrometry. *Rapid Commun. Mass Spectrom.* 1991, 5, 383–386.
31. Allikmaa, V.; Lopp, M.; Pehk, T.; Peterson, J. Fragmentation of pamam dendrimers in methanol. *Proc. Estonian Acad. Sci. Chem.* 2001, 50, 167–172.
32. Fischer, D.; Li, Y.; Ahlemeyer, B.; Krieglstein, J.; Kissel, T. In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. *Biomaterials* 2002, 24, 1121–1131.
33. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity. *Adv. Drug Deliv. Rev.* 2005, 57, 2215–2237.
34. Labieniec-Watala, M.; Watala, C. PAMAM Dendrimers: Destined for Success or Doomed to Fail? Plain and Modified PAMAM Dendrimers in the Context of Biomedical Applications. *J. Pharm. Sci.* 2015, 104, 2–14.
35. Baklouti, L.; Cheriaa, N.; Mahouachi, M.; Abidi, R.; Kim, J.S.; Kim, Y.; Vicens, J. Calixarene-Based Dendrimers. A Timely Review. *J. Incl. Phenom. Macrocycl. Chem.* 2006, 54, 1–7.
36. Rahimi, M.; Karimian, R.; Mostafidi, E.; Noruzi, E.B.; Taghizadeh, S.; Shokouhi, B.; Kafil, H.S. Highly branched amine-functionalized p-sulfonatocalixarene decorated with human plasma proteins as a smart, targeted, and stealthy nano-vehicle for the combination chemotherapy of MCF7 cells. *New J. Chem.* 2018, 42, 13010–13024.
37. Ficker, M.; Paolucci, V.; Christensen, J.B. Improved large-scale synthesis and characterization of small and medium generation PAMAM dendrimers. *Can. J. Chem.* 2017, 95, 954–964.
38. Tomalia, D.A.; Naylor, A.M.; Ili, W.A.G. Starburst Dendrimers: Molecular-Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter. *Angew. Chem. Int. Ed.* 1990, 29, 138–175.

39. Mostovaya, O.A.; Gorbachuk, V.V.; Bazanova, O.B.; Gerasimov, A.V.; Evtugyn, V.G.; Osin, Y.N.; Myakushev, V.D.; Rizvanov, I.K.; Stoikov, I.I. Thiacalixarene “knot” effect on protein binding by oligolactic acid particles. *Mater. Chem. Front.* 2018, 3, 292–300.
40. Mostovaya, O.A.; Padnya, P.; Shurpik, D.; Vavilova, A.; Evtugyn, V.G.; Osin, Y.; Stoikov, I.I. Iminodiacetic Derivatives of p-tert-Butylthiacalixarene: Synthesis and Influence of Conformation on the Aggregation with Bismarck Brown Y. *Macrocyclics* 2017, 10, 154–163.
41. Padnya, P.; Shibaeva, K.; Arsenyev, M.; Baryshnikova, S.; Terenteva, O.; Shiabiev, I.; Khannanov, A.; Boldyrev, A.; Gerasimov, A.; Grishaev, D.; et al. Catechol-Containing Schiff Bases on Thiacalixarene: Synthesis, Copper (II) Recognition, and Formation of Organic-Inorganic Copper-Based Materials. *Molecules* 2021, 26, 2334.

---

Retrieved from <https://encyclopedia.pub/entry/history/show/37693>